Does the media favor BIOA or FULC?

In the previous week, Fulcrum Therapeutics had 2 more articles in the media than BioAge Labs. MarketBeat recorded 3 mentions for Fulcrum Therapeutics and 1 mentions for BioAge Labs. Fulcrum Therapeutics' average media sentiment score of 0.10 beat BioAge Labs' score of 0.00 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fulcrum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer XNCR or FULC?

In the previous week, Xencor had 1 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 4 mentions for Xencor and 3 mentions for Fulcrum Therapeutics. Xencor's average media sentiment score of 0.65 beat Fulcrum Therapeutics' score of 0.10 indicating that Xencor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fulcrum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer FULC or MGTX?

In the previous week, Fulcrum Therapeutics had 1 more articles in the media than MeiraGTx. MarketBeat recorded 3 mentions for Fulcrum Therapeutics and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.96 beat Fulcrum Therapeutics' score of 0.10 indicating that MeiraGTx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral MeiraGTx 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor FULC or ETON?

In the previous week, Fulcrum Therapeutics and Fulcrum Therapeutics both had 3 articles in the media. Fulcrum Therapeutics' average media sentiment score of 0.10 beat Eton Pharmaceuticals' score of -0.04 indicating that Fulcrum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Fulcrum Therapeutics (FULC) Competitors

$3.85 +0.08 (+2.12%)

As of 04:00 PM Eastern

Compare

FULC vs. BIOA, XNCR, MGTX, PHAR, and ETON

Should you buy Fulcrum Therapeutics stock or one of its competitors? MarketBeat compares Fulcrum Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fulcrum Therapeutics include BioAge Labs (BIOA), Xencor (XNCR), MeiraGTx (MGTX), Pharming Group (PHAR), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry.

How does Fulcrum Therapeutics compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Fulcrum Therapeutics has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. Fulcrum Therapeutics' return on equity of -27.80% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
Fulcrum Therapeutics	N/A	-27.80%	-26.32%

BioAge Labs currently has a consensus target price of $43.50, suggesting a potential upside of 94.89%. Fulcrum Therapeutics has a consensus target price of $8.20, suggesting a potential upside of 112.99%. Given Fulcrum Therapeutics' higher probable upside, analysts plainly believe Fulcrum Therapeutics is more favorable than BioAge Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Fulcrum Therapeutics had 2 more articles in the media than BioAge Labs. MarketBeat recorded 3 mentions for Fulcrum Therapeutics and 1 mentions for BioAge Labs. Fulcrum Therapeutics' average media sentiment score of 0.10 beat BioAge Labs' score of 0.00 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fulcrum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 20.8% of BioAge Labs shares are owned by company insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BioAge Labs has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 2.93, meaning that its stock price is 193% more volatile than the broader market.

Fulcrum Therapeutics has higher revenue and earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	110.36	-$80.61M	-$2.40	N/A
Fulcrum Therapeutics	$80M	3.21	-$74.88M	-$1.15	N/A

Summary

Fulcrum Therapeutics beats BioAge Labs on 11 of the 15 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Xencor?

Xencor (NASDAQ:XNCR) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Fulcrum Therapeutics has lower revenue, but higher earnings than Xencor. Xencor is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xencor	$125.58M	8.31	-$91.92M	-$2.29	N/A
Fulcrum Therapeutics	$80M	3.21	-$74.88M	-$1.15	N/A

Xencor presently has a consensus target price of $24.50, indicating a potential upside of 74.01%. Fulcrum Therapeutics has a consensus target price of $8.20, indicating a potential upside of 112.99%. Given Fulcrum Therapeutics' higher possible upside, analysts clearly believe Fulcrum Therapeutics is more favorable than Xencor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xencor	2 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Fulcrum Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -177.10%. Fulcrum Therapeutics' return on equity of -27.80% beat Xencor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xencor	-177.10%	-28.77%	-20.52%
Fulcrum Therapeutics	N/A	-27.80%	-26.32%

89.8% of Fulcrum Therapeutics shares are held by institutional investors. 5.1% of Xencor shares are held by company insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Xencor had 1 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 4 mentions for Xencor and 3 mentions for Fulcrum Therapeutics. Xencor's average media sentiment score of 0.65 beat Fulcrum Therapeutics' score of 0.10 indicating that Xencor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xencor	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulcrum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xencor has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 2.93, indicating that its stock price is 193% more volatile than the broader market.

Summary

Fulcrum Therapeutics beats Xencor on 9 of the 16 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to MeiraGTx?

Fulcrum Therapeutics (NASDAQ:FULC) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

Fulcrum Therapeutics has higher earnings, but lower revenue than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80M	3.21	-$74.88M	-$1.15	N/A
MeiraGTx	$81.39M	13.44	-$114.20M	-$1.48	N/A

Fulcrum Therapeutics has a net margin of 0.00% compared to MeiraGTx's net margin of -151.12%. Fulcrum Therapeutics' return on equity of -27.80% beat MeiraGTx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-27.80%	-26.32%
MeiraGTx	-151.12%	-1,065.47%	-54.96%

89.8% of Fulcrum Therapeutics shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 7.3% of Fulcrum Therapeutics shares are held by company insiders. Comparatively, 7.4% of MeiraGTx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Fulcrum Therapeutics has a beta of 2.93, suggesting that its share price is 193% more volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

In the previous week, Fulcrum Therapeutics had 1 more articles in the media than MeiraGTx. MarketBeat recorded 3 mentions for Fulcrum Therapeutics and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.96 beat Fulcrum Therapeutics' score of 0.10 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulcrum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
MeiraGTx	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fulcrum Therapeutics currently has a consensus price target of $8.20, suggesting a potential upside of 112.99%. MeiraGTx has a consensus price target of $25.83, suggesting a potential upside of 118.74%. Given MeiraGTx's stronger consensus rating and higher probable upside, analysts clearly believe MeiraGTx is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
MeiraGTx	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Fulcrum Therapeutics beats MeiraGTx on 9 of the 17 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

In the previous week, Fulcrum Therapeutics had 3 more articles in the media than Pharming Group. MarketBeat recorded 3 mentions for Fulcrum Therapeutics and 0 mentions for Pharming Group. Fulcrum Therapeutics' average media sentiment score of 0.10 beat Pharming Group's score of 0.00 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Pharming Group	Neutral
Fulcrum Therapeutics	Neutral

Pharming Group has a net margin of 3.30% compared to Fulcrum Therapeutics' net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Fulcrum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	3.30%	4.64%	2.55%
Fulcrum Therapeutics	N/A	-27.80%	-26.32%

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Pharming Group has higher revenue and earnings than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	2.42	$2.85M	$0.16	80.44
Fulcrum Therapeutics	$80M	3.21	-$74.88M	-$1.15	N/A

Pharming Group has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 2.93, meaning that its stock price is 193% more volatile than the broader market.

Pharming Group currently has a consensus price target of $38.33, indicating a potential upside of 197.85%. Fulcrum Therapeutics has a consensus price target of $8.20, indicating a potential upside of 112.99%. Given Pharming Group's stronger consensus rating and higher probable upside, analysts clearly believe Pharming Group is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Summary

Pharming Group beats Fulcrum Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Fulcrum Therapeutics compare to Eton Pharmaceuticals?

Fulcrum Therapeutics (NASDAQ:FULC) and Eton Pharmaceuticals (NASDAQ:ETON) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 7.3% of Fulcrum Therapeutics shares are owned by company insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Fulcrum Therapeutics and Fulcrum Therapeutics both had 3 articles in the media. Fulcrum Therapeutics' average media sentiment score of 0.10 beat Eton Pharmaceuticals' score of -0.04 indicating that Fulcrum Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulcrum Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eton Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fulcrum Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Eton Pharmaceuticals' return on equity of -5.68% beat Fulcrum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulcrum Therapeutics	N/A	-27.80%	-26.32%
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%

Fulcrum Therapeutics currently has a consensus target price of $8.20, suggesting a potential upside of 112.99%. Eton Pharmaceuticals has a consensus target price of $41.00, suggesting a potential upside of 22.42%. Given Fulcrum Therapeutics' higher possible upside, analysts clearly believe Fulcrum Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulcrum Therapeutics	4 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Fulcrum Therapeutics has a beta of 2.93, meaning that its share price is 193% more volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

Eton Pharmaceuticals has lower revenue, but higher earnings than Fulcrum Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulcrum Therapeutics	$80M	3.21	-$74.88M	-$1.15	N/A
Eton Pharmaceuticals	$79.95M	11.47	-$4.60M	-$0.07	N/A

Summary

Eton Pharmaceuticals beats Fulcrum Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Fulcrum Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FULC vs. The Competition

Export

Metric	Fulcrum Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$251.21M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-3.35	11.07	21.07	22.20
Price / Sales	3.21	334.82	530.36	110.15
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	0.60	8.29	10.79	6.50
Net Income	-$74.88M	$23.85M	$3.56B	$336.88M
7 Day Performance	11.27%	5.21%	1.67%	-0.22%
1 Month Performance	-41.40%	2.19%	0.43%	0.77%
1 Year Performance	-46.30%	60.99%	32.84%	31.57%

Fulcrum Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FULC Fulcrum Therapeutics	2.635 of 5 stars	$3.85 +2.1%	$8.20 +113.0%	-46.1%	$251.21M	$80M	N/A	100	Gap Down
BIOA BioAge Labs	2.4645 of 5 stars	$20.57 +3.7%	$43.50 +111.5%	N/A	$914.11M	$8.99M	N/A	N/A	News Coverage
XNCR Xencor	1.9 of 5 stars	$12.23 +0.2%	$24.50 +100.3%	+64.1%	$906.66M	$125.58M	N/A	280	Positive News
MGTX MeiraGTx	3.1401 of 5 stars	$9.71 -0.5%	$25.83 +166.2%	+81.1%	$898.87M	$81.39M	N/A	300
PHAR Pharming Group	3.6776 of 5 stars	$12.64 -1.3%	$38.33 +203.3%	+19.9%	$892.64M	$376.13M	79.00	280	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FULC) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fulcrum Therapeutics (FULC) Competitors

FULC vs. BIOA, XNCR, MGTX, PHAR, and ETON

How does Fulcrum Therapeutics compare to BioAge Labs?

Summary

How does Fulcrum Therapeutics compare to Xencor?

Summary

How does Fulcrum Therapeutics compare to MeiraGTx?

Summary

How does Fulcrum Therapeutics compare to Pharming Group?

Summary

How does Fulcrum Therapeutics compare to Eton Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FULC vs. The Competition

Fulcrum Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fulcrum Therapeutics (FULC) Competitors

FULC vs. BIOA, XNCR, MGTX, PHAR, and ETON

How does Fulcrum Therapeutics compare to BioAge Labs?

Is BIOA or FULC more profitable?

Do analysts rate BIOA or FULC?

Does the media favor BIOA or FULC?

Do insiders & institutionals hold more shares of BIOA or FULC?

Which has more volatility & risk, BIOA or FULC?

Which has preferable valuation and earnings, BIOA or FULC?

Summary

How does Fulcrum Therapeutics compare to Xencor?

Which has higher earnings and valuation, XNCR or FULC?

Do analysts rate XNCR or FULC?

Is XNCR or FULC more profitable?

Do insiders and institutionals hold more shares of XNCR or FULC?

Does the media prefer XNCR or FULC?

Which has more risk & volatility, XNCR or FULC?

Summary

How does Fulcrum Therapeutics compare to MeiraGTx?

Which has preferable valuation & earnings, FULC or MGTX?

Is FULC or MGTX more profitable?

Do insiders & institutionals hold more shares of FULC or MGTX?

Which has more volatility and risk, FULC or MGTX?

Does the media prefer FULC or MGTX?

Do analysts prefer FULC or MGTX?

Summary

How does Fulcrum Therapeutics compare to Pharming Group?

Does the media prefer PHAR or FULC?

Is PHAR or FULC more profitable?

Do insiders and institutionals have more ownership in PHAR or FULC?

Which has stronger valuation & earnings, PHAR or FULC?

Which has more volatility & risk, PHAR or FULC?

Do analysts prefer PHAR or FULC?

Summary

How does Fulcrum Therapeutics compare to Eton Pharmaceuticals?

Do insiders and institutionals have more ownership in FULC or ETON?

Does the media favor FULC or ETON?

Is FULC or ETON more profitable?

Do analysts rate FULC or ETON?

Which has more risk & volatility, FULC or ETON?

Which has higher earnings and valuation, FULC or ETON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FULC vs. The Competition

Fulcrum Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools